NOAEL Studies Cosmetic Ingredient

Lauroyl Sarcosine NOAEL Studies

INCI: LAUROYL SARCOSINE

CAS: 97-78-9

Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.

Back to parent ingredient page
CIR_vision_codex 16 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
CIR_vision_codex NOAEL =1000 mg/kg/day rat oral 6 months oral toxicity {"citation":"2; 5; 1","dose":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group give...","effect":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group given 2500 g/kg. Weanling rats fed 0.5–2% Sodium Lauroyl Sarcosinate for up to 6 months had no signs of toxicity. During a 2-year feeding study using Wistar rats, the no-observed-effect level of So- dium Lauroyl Sarcosinate was 1000 mg/kg/day. Acute Toxicity Studies Dermal Sodium Myristoyl Sarcosinate. A dose of 2000 mg/kg So- dium Myristoyl Sarcosinate in arachis oil was applied for 24 hours to the backs and flanks of 5 male and 5 female RCC Han:WIST rats using semi-occlusive patches.25 Approxi- mately 10% of the body was covered. Observations were made 0.5, 1, 2, and 4 hours after dosing and then once daily for 14 days. All animals survived until study termination. Very slight erythema, which was observed in 7/10 animals, was fully...","page":10,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_001"}
CIR_vision_codex NOAEL =250 mg/kg/day - - - developmental toxicity {"citation":"8; 11; 14","dose":"Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation.","effect":"8–11 and days 14–17 of gestation. Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation. The dam that died on day 18 of gestation had sloughing on the non-glandular region of the stomach, 7 dead fetuses had sloughing in the right uterine horn, and 5 dead fetuses had sloughing in the left uterine horn, and the high- dose females killed at study termination all had sloughing on the non-glandular region of the stomach; this effect was not observed in the low- or mid-dose groups. The NOAEL (maternal toxicity), LOAEL (maternal toxicity), and NOEL (developmental toxicity) were 30, 100, and ≥250 mg/kg/day Sodium Lauroyl Sarcosinate, respectively. Genotoxicity In Vitro Sodium Lauroyl Sarcosinate was not considered mutagenic in five strains of Salmonella typhimurium during plate Fiume et al. 127S","page":11,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_002"}
CIR_vision_codex NOAEL =96.2 % rat oral 28-day developmental toxicity {"citation":"30, 100; 250; 4","dose":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively.","effect":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours with...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_004"}
CIR_vision_codex NOAEL =30 mg/kg/day rat oral 28-day developmental toxicity {"citation":"1; 85; (34","dose":"No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation.","effect":"– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours without metabolic activation) was not genotoxic in an in vitro mammalian chromosomal aberration assay in lymphocytes. Sodium Lauroyl Sarcosinate was non-corrosive to re- constructed human epidermis in an In Vitro Skin Corrosion Human Skin Model Test. Undiluted Oleoyl Sarcosine wa...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_005"}
CIR_vision_codex NOAEL =1000 mg/kg/day rat oral 6 months oral toxicity {"citation":"2; 5; 1","dose":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group give...","effect":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group given 2500 g/kg. Weanling rats fed 0.5–2% Sodium Lauroyl Sarcosinate for up to 6 months had no signs of toxicity. During a 2-year feeding study using Wistar rats, the no-observed-effect level of So- dium Lauroyl Sarcosinate was 1000 mg/kg/day. Acute Toxicity Studies Dermal Sodium Myristoyl Sarcosinate. A dose of 2000 mg/kg So- dium Myristoyl Sarcosinate in arachis oil was applied for 24 hours to the backs and flanks of 5 male and 5 female RCC Han:WIST rats using semi-occlusive patches.25 Approxi- mately 10% of the body was covered. Observations were made 0.5, 1, 2, and 4 hours after dosing and then once daily for 14 days. All animals survived until study termination. Very slight erythema, which was observed in 7/10 animals, was fully...","page":10,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_001"}
CIR_vision_codex NOAEL =250 mg/kg/day - - - developmental toxicity {"citation":"8; 11; 14","dose":"Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation.","effect":"8–11 and days 14–17 of gestation. Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation. The dam that died on day 18 of gestation had sloughing on the non-glandular region of the stomach, 7 dead fetuses had sloughing in the right uterine horn, and 5 dead fetuses had sloughing in the left uterine horn, and the high- dose females killed at study termination all had sloughing on the non-glandular region of the stomach; this effect was not observed in the low- or mid-dose groups. The NOAEL (maternal toxicity), LOAEL (maternal toxicity), and NOEL (developmental toxicity) were 30, 100, and ≥250 mg/kg/day Sodium Lauroyl Sarcosinate, respectively. Genotoxicity In Vitro Sodium Lauroyl Sarcosinate was not considered mutagenic in five strains of Salmonella typhimurium during plate Fiume et al. 127S","page":11,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_002"}
CIR_vision_codex NOAEL =96.2 % rat oral 28-day developmental toxicity {"citation":"30, 100; 250; 4","dose":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively.","effect":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours with...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_004"}
CIR_vision_codex NOAEL =30 mg/kg/day rat oral 28-day developmental toxicity {"citation":"1; 85; (34","dose":"No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation.","effect":"– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours without metabolic activation) was not genotoxic in an in vitro mammalian chromosomal aberration assay in lymphocytes. Sodium Lauroyl Sarcosinate was non-corrosive to re- constructed human epidermis in an In Vitro Skin Corrosion Human Skin Model Test. Undiluted Oleoyl Sarcosine wa...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_005"}
CIR_vision_codex NOAEL =1000 mg/kg/day rat oral 6 months oral toxicity {"citation":"2; 5; 1","dose":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group give...","effect":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group given 2500 g/kg. Weanling rats fed 0.5–2% Sodium Lauroyl Sarcosinate for up to 6 months had no signs of toxicity. During a 2-year feeding study using Wistar rats, the no-observed-effect level of So- dium Lauroyl Sarcosinate was 1000 mg/kg/day. Acute Toxicity Studies Dermal Sodium Myristoyl Sarcosinate. A dose of 2000 mg/kg So- dium Myristoyl Sarcosinate in arachis oil was applied for 24 hours to the backs and flanks of 5 male and 5 female RCC Han:WIST rats using semi-occlusive patches.25 Approxi- mately 10% of the body was covered. Observations were made 0.5, 1, 2, and 4 hours after dosing and then once daily for 14 days. All animals survived until study termination. Very slight erythema, which was observed in 7/10 animals, was fully...","page":10,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_001"}
CIR_vision_codex NOAEL =250 mg/kg/day - - - developmental toxicity {"citation":"8; 11; 14","dose":"Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation.","effect":"8–11 and days 14–17 of gestation. Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation. The dam that died on day 18 of gestation had sloughing on the non-glandular region of the stomach, 7 dead fetuses had sloughing in the right uterine horn, and 5 dead fetuses had sloughing in the left uterine horn, and the high- dose females killed at study termination all had sloughing on the non-glandular region of the stomach; this effect was not observed in the low- or mid-dose groups. The NOAEL (maternal toxicity), LOAEL (maternal toxicity), and NOEL (developmental toxicity) were 30, 100, and ≥250 mg/kg/day Sodium Lauroyl Sarcosinate, respectively. Genotoxicity In Vitro Sodium Lauroyl Sarcosinate was not considered mutagenic in five strains of Salmonella typhimurium during plate Fiume et al. 127S","page":11,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_002"}
CIR_vision_codex NOAEL =96.2 % rat oral 28-day developmental toxicity {"citation":"30, 100; 250; 4","dose":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively.","effect":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours with...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_004"}
CIR_vision_codex NOAEL =30 mg/kg/day rat oral 28-day developmental toxicity {"citation":"1; 85; (34","dose":"No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation.","effect":"– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours without metabolic activation) was not genotoxic in an in vitro mammalian chromosomal aberration assay in lymphocytes. Sodium Lauroyl Sarcosinate was non-corrosive to re- constructed human epidermis in an In Vitro Skin Corrosion Human Skin Model Test. Undiluted Oleoyl Sarcosine wa...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_005"}
CIR_vision_codex NOAEL =1000 mg/kg/day rat oral 6 months oral toxicity {"citation":"2; 5; 1","dose":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group give...","effect":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group given 2500 g/kg. Weanling rats fed 0.5–2% Sodium Lauroyl Sarcosinate for up to 6 months had no signs of toxicity. During a 2-year feeding study using Wistar rats, the no-observed-effect level of So- dium Lauroyl Sarcosinate was 1000 mg/kg/day. Acute Toxicity Studies Dermal Sodium Myristoyl Sarcosinate. A dose of 2000 mg/kg So- dium Myristoyl Sarcosinate in arachis oil was applied for 24 hours to the backs and flanks of 5 male and 5 female RCC Han:WIST rats using semi-occlusive patches.25 Approxi- mately 10% of the body was covered. Observations were made 0.5, 1, 2, and 4 hours after dosing and then once daily for 14 days. All animals survived until study termination. Very slight erythema, which was observed in 7/10 animals, was fully...","page":10,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_001"}
CIR_vision_codex NOAEL =250 mg/kg/day - - - developmental toxicity {"citation":"8; 11; 14","dose":"Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation.","effect":"8–11 and days 14–17 of gestation. Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation. The dam that died on day 18 of gestation had sloughing on the non-glandular region of the stomach, 7 dead fetuses had sloughing in the right uterine horn, and 5 dead fetuses had sloughing in the left uterine horn, and the high- dose females killed at study termination all had sloughing on the non-glandular region of the stomach; this effect was not observed in the low- or mid-dose groups. The NOAEL (maternal toxicity), LOAEL (maternal toxicity), and NOEL (developmental toxicity) were 30, 100, and ≥250 mg/kg/day Sodium Lauroyl Sarcosinate, respectively. Genotoxicity In Vitro Sodium Lauroyl Sarcosinate was not considered mutagenic in five strains of Salmonella typhimurium during plate Fiume et al. 127S","page":11,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_002"}
CIR_vision_codex NOAEL =96.2 % rat oral 28-day developmental toxicity {"citation":"30, 100; 250; 4","dose":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively.","effect":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours with...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_004"}
CIR_vision_codex NOAEL =30 mg/kg/day rat oral 28-day developmental toxicity {"citation":"1; 85; (34","dose":"No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation.","effect":"– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours without metabolic activation) was not genotoxic in an in vitro mammalian chromosomal aberration assay in lymphocytes. Sodium Lauroyl Sarcosinate was non-corrosive to re- constructed human epidermis in an In Vitro Skin Corrosion Human Skin Model Test. Undiluted Oleoyl Sarcosine wa...","page":14,"pdf":"PRS719.pdf","row_type":"noael_study","study_id":"PRS719_noael_005"}
NTP_ICE_adme_parameters 2 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
NTP_ICE_adme_parameters Clint 42.07 uL/min/10^6 cells Human - - Measured; httk, Human Hepatic Intrinsic Clearance sheet=Data; excel_row=2976; Record_ID=adme_parameters_1212; Data_Type=Measured; DTXSID=DTXSID7042011; Assay=httk, Human Hepatic Intrinsic Clearance; Endpoint=Clint; Response=42.07; Response_Unit=ul/min/10^6 cells; Species=Human; Reference=httk2.3.1, Paini 2020; URL=https://cran.r-project.org/web/packages/httk/index.html; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID7042011
NTP_ICE_adme_parameters Fu 0.003219 fraction Human - - Measured; httk, Human Plasma Fraction Unbound sheet=Data; excel_row=2975; Record_ID=adme_parameters_1212; Data_Type=Measured; DTXSID=DTXSID7042011; Assay=httk, Human Plasma Fraction Unbound; Endpoint=Fu; Response=0.003219; Response_Unit=Unitless Fraction; Species=Human; Reference=httk2.3.1, Paini 2020; URL=https://cran.r-project.org/web/packages/httk/index.html; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID7042011
NTP_ICE_endocrine 1 endpoint
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
NTP_ICE_endocrine Model Score 0 unitless - - - ARPathway2016; AR Pathway Model, Antagonist sheet=Integrated_approaches; excel_row=12100; RecordID=ARPathway2016_1791; DatasetName=ARPathway2016; DTXSID=DTXSID7042011; Assay=AR Pathway Model, Antagonist; Endpoint=Model Score; Response=0; Response_Unit=Unitless; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID7042011
ToxValDB_GESTIS_DNEL 1 endpoint
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
ToxValDB_GESTIS_DNEL DNEL systemic =141.053 mg/m3 Human inhalation - Toxicity Value STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/6543dd69e4b045b9ff7cd87e; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://www.dguv.de/ifa/gestis/gestis-dnel-liste/index-2.jsp; STUDY_GROUP=GESTIS DNEL:15632932:-:--; QC_CATEGORY=Programmatically extracted from structured data source; Source overall passed QC, but this record was not manually checked; QC_STATUS=not determined; SOURCE_HASH=ToxValhc_00d87180ddff05dda33bf28deb6d4ea2
UnifiedCodex:CIR:beta.noael_studies 5 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
UnifiedCodex:CIR:beta.noael_studies developmental toxicity >=250 mg/kg/day - - - developmental toxicity SOURCE_SUBDIR=PRS719; REPORT_TITLE=Amended Safety Assessment of Fatty Acyl Sarcosines and Sarcosinate Salts as Used in Cosmetics Monice M. Fiume*, Wilma F. Bergfeld**, Donald V. Belsito**, Ronald A. Hill***, Curtis D. Klaassen**, Daniel C. Liebler**, James G. Marks Jr.***, R; OPINION_NUMBER=PRS719; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=3 In 1987; VALUE_TEXT=≥ 250; DOSE=Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation.; LOAEL_VALUE=≥250 mg/kg/day; EFFECT=8–11 and days 14–17 of gestation. Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation. The dam that died on day 18 of gestation had sloughing on the non-glandular region of the stomach, 7 dead fetuses had sloughing in the right uterine horn, and 5 dead fetuses had sloughing in the left uterine horn, and the high- dose females killed at study termination all had sloughing on the non-glandular region of the stomach; this effect was not observed in the low- or mid-dose groups. The NOAEL (maternal toxicity), LOAEL (maternal toxicity), and NOEL (developmental toxicity) were 30, 100, and ≥250 mg/kg/day Sodium Lauroyl Sarcosinate, respectively. Genotoxicity In Vitro Sodium Lauroyl Sarcosinate was not considered mutagenic in five strains of Salmonella typhimurium during plate Fiume et al. 127S; CITATION=8; 11; 14; CITATION_NUMBERS=[8,11,14]; REFERENCE=8; 11; 14; DETAILS_JSON={"cas_number":"97-78-9","citation":"8; 11; 14","dose":"Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation.","duration":"","effect":"8–11 and days 14–17 of gestation. Two high- dose dams died during the study, one on day 10 and one on day 18 of gestation. The dam that died on day 18 of gestation had sloughing on the non-glandular region of the stomach, 7 dead fetuses had sloughing in the right uterine horn, and 5 dead fetuses had sloughing in the left uterine horn, and the high- dose females killed at study termination all had sloughing on the non-glandular region of the stomach; this effect was not observed in the low- or mid-dose groups. The NOAEL (maternal toxicity), LOAEL (maternal toxicity), and NOEL (developmental toxicity) were 30, 100, and ≥250 mg/kg/day Sodium Lauroyl Sarcosinate, respectively. Genotoxicity In Vitro Sodium Lauroyl Sarcosinate was not considered mutagenic in five strains of Salmonella typhimurium during plate Fiume et al. 127S","endpoint":"developmental toxicity","ingredient":"Fatty Acyl Sarcosines and Sarcosinate Salts","loael_value":"≥250 mg/kg/day","noael_unit":"mg/kg/day","noael_value":"≥ 250","page":11,"route":"","species":"","study_id":"PRS719_noael_002"}
UnifiedCodex:CIR:beta.noael_studies developmental toxicity 96.2 % rat oral 28-day developmental toxicity SOURCE_SUBDIR=PRS719; REPORT_TITLE=Amended Safety Assessment of Fatty Acyl Sarcosines and Sarcosinate Salts as Used in Cosmetics Monice M. Fiume*, Wilma F. Bergfeld**, Donald V. Belsito**, Ronald A. Hill***, Curtis D. Klaassen**, Daniel C. Liebler**, James G. Marks Jr.***, R; OPINION_NUMBER=PRS719; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=3 In 1987; VALUE_TEXT=96.2; DOSE=onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively.; LOAEL_VALUE=250 mg/kg/day; EFFECT=onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours with...; CITATION=30, 100; 250; 4; CITATION_NUMBERS=[30,100,250,4]; REFERENCE=30, 100; 250; 4; DETAILS_JSON={"cas_number":"97-78-9","citation":"30, 100; 250; 4","dose":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively.","duration":"28-day","effect":"onth gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours with...","endpoint":"developmental toxicity","ingredient":"Fatty Acyl Sarcosines and Sarcosinate Salts","loael_value":"250 mg/kg/day","noael_unit":"%","noael_value":"96.2","page":14,"route":"oral","species":"rat","study_id":"PRS719_noael_004"}
UnifiedCodex:CIR:beta.noael_studies developmental toxicity 30 mg/kg/day rat oral 28-day developmental toxicity SOURCE_SUBDIR=PRS719; REPORT_TITLE=Amended Safety Assessment of Fatty Acyl Sarcosines and Sarcosinate Salts as Used in Cosmetics Monice M. Fiume*, Wilma F. Bergfeld**, Donald V. Belsito**, Ronald A. Hill***, Curtis D. Klaassen**, Daniel C. Liebler**, James G. Marks Jr.***, R; OPINION_NUMBER=PRS719; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=3 In 1987; VALUE_TEXT=30 and 100; DOSE=No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation.; LOAEL_VALUE=100 mg/kg/day; EFFECT=– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours without metabolic activation) was not genotoxic in an in vitro mammalian chromosomal aberration assay in lymphocytes. Sodium Lauroyl Sarcosinate was non-corrosive to re- constructed human epidermis in an In Vitro Skin Corrosion Human Skin Model Test. Undiluted Oleoyl Sarcosine wa...; CITATION=1; 85; (34; CITATION_NUMBERS=[1,85,34]; REFERENCE=1; 85; (34; DETAILS_JSON={"cas_number":"97-78-9","citation":"1; 85; (34","dose":"No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation.","duration":"28-day","effect":"– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prenatal developmental toxicity study in which gravid rats were dosed by gavage with up to 250 mg/kg/day Sodium Lauroyl Sarcosinate on days 5–10 of gestation. The NOAEL and LOAEL for maternal toxicity were 30 and 100 mg/kg/day. Oleoyl Sarcosine was not mutagenic in an Ames test (≥5000 μg/plate, with or without metabolic activation), and Sodium Lauroyl Sarcosinate (22.5–360 μg/mL for 4 hours with or without metabolic activation; 22.5–270 μg/mL for 24 hours without metabolic activation) was not genotoxic in an in vitro mammalian chromosomal aberration assay in lymphocytes. Sodium Lauroyl Sarcosinate was non-corrosive to re- constructed human epidermis in an In Vitro Skin Corrosion Human Skin Model Test. Undiluted Oleoyl Sarcosine wa...","endpoint":"developmental toxicity","ingredient":"Fatty Acyl Sarcosines and Sarcosinate Salts","loael_value":"100 mg/kg/day","noael_unit":"mg/kg/day","noael_value":"30 and 100","page":14,"route":"oral","species":"rat","study_id":"PRS719_noael_005"}
UnifiedCodex:CIR:beta.noael_studies inhalation toxicity 250 mg/kg/day rat oral 3- month inhalation toxicity SOURCE_SUBDIR=PRS719; REPORT_TITLE=Amended Safety Assessment of Fatty Acyl Sarcosines and Sarcosinate Salts as Used in Cosmetics Monice M. Fiume*, Wilma F. Bergfeld**, Donald V. Belsito**, Ronald A. Hill***, Curtis D. Klaassen**, Daniel C. Liebler**, James G. Marks Jr.***, R; OPINION_NUMBER=PRS719; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=3 In 1987; VALUE_TEXT=250; DOSE=Sodium Myristoyl Sarcosinate had a dermal LD50 of >2000 mg/kg in male and female rats.; LOAEL_VALUE=250 mg/kg/day; EFFECT=an cadaver epidermis using 3% lauroyl sarcosine in aq. 50% ethanol. Lauroyl Sarcosine and Sodium Lauroyl Sarcosinate alone (in PBS) did not significantly affect penetration. Sodium Myristoyl Sarcosinate had a dermal LD50 of >2000 mg/kg in male and female rats. In acute oral studies in rats, oleoyl sarcosine had an LD50 of 9200 mg/kg, Sodium Lauroyl Sarcosinate had an LD50 of >5000 mg/kg, and So- dium Oleoyl Sarcosinate had an LD50 of 6000 mg/kg. In a 3- month gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prena...; CITATION=3; 50; 30, 100; CITATION_NUMBERS=[3,50,30,100]; REFERENCE=3; 50; 30, 100; DETAILS_JSON={"cas_number":"97-78-9","citation":"3; 50; 30, 100","dose":"Sodium Myristoyl Sarcosinate had a dermal LD50 of >2000 mg/kg in male and female rats.","duration":"3- month","effect":"an cadaver epidermis using 3% lauroyl sarcosine in aq. 50% ethanol. Lauroyl Sarcosine and Sodium Lauroyl Sarcosinate alone (in PBS) did not significantly affect penetration. Sodium Myristoyl Sarcosinate had a dermal LD50 of >2000 mg/kg in male and female rats. In acute oral studies in rats, oleoyl sarcosine had an LD50 of 9200 mg/kg, Sodium Lauroyl Sarcosinate had an LD50 of >5000 mg/kg, and So- dium Oleoyl Sarcosinate had an LD50 of 6000 mg/kg. In a 3- month gavage study of Sodium Lauroyl Sarcosinate in rats, the NOEL, LOAEL (local effects), and NOAEL (systemic effects) were 30, 100, and 250 mg/kg/day, respectively. Acute inhalation studies were performed in rats; with a 4- hour exposure, Oleoyl Sarcosine had a LC50 of >1.01– 1.85 mg/L air, Sodium Lauroyl Sarcosinate (34.5% pure) had an LC50 between 1 and 5%, and Sodium Lauroyl Sarcosinate (96.2% pure) had an LC50 of 0.05–0.5 mg/L air. A 28-day inhalation study was performed in rats with Oleoyl Sarcosi- nate; the NOEL was <0.006 mg/L air, and the NOAEC was 0.06 mg/L air. No embryotoxicity or teratogenicity was observed in a prena...","endpoint":"inhalation toxicity","ingredient":"Fatty Acyl Sarcosines and Sarcosinate Salts","loael_value":"250 mg/kg/day","noael_unit":"mg/kg/day","noael_value":"250","page":14,"route":"oral","species":"rat","study_id":"PRS719_noael_003"}
UnifiedCodex:CIR:beta.noael_studies oral toxicity 1000 mg/kg/day rat oral 6 months oral toxicity SOURCE_SUBDIR=PRS719; REPORT_TITLE=Amended Safety Assessment of Fatty Acyl Sarcosines and Sarcosinate Salts as Used in Cosmetics Monice M. Fiume*, Wilma F. Bergfeld**, Donald V. Belsito**, Ronald A. Hill***, Curtis D. Klaassen**, Daniel C. Liebler**, James G. Marks Jr.***, R; OPINION_NUMBER=PRS719; COMMITTEE=Expert Panel for Cosmetic Ingredient Safety; REPORT_DATE=3 In 1987; VALUE_TEXT=1000; DOSE=le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group give...; EFFECT=le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group given 2500 g/kg. Weanling rats fed 0.5–2% Sodium Lauroyl Sarcosinate for up to 6 months had no signs of toxicity. During a 2-year feeding study using Wistar rats, the no-observed-effect level of So- dium Lauroyl Sarcosinate was 1000 mg/kg/day. Acute Toxicity Studies Dermal Sodium Myristoyl Sarcosinate. A dose of 2000 mg/kg So- dium Myristoyl Sarcosinate in arachis oil was applied for 24 hours to the backs and flanks of 5 male and 5 female RCC Han:WIST rats using semi-occlusive patches.25 Approxi- mately 10% of the body was covered. Observations were made 0.5, 1, 2, and 4 hours after dosing and then once daily for 14 days. All animals survived until study termination. Very slight erythema, which was observed in 7/10 animals, was fully...; CITATION=2; 5; 1; CITATION_NUMBERS=[2,5,1]; REFERENCE=2; 5; 1; DETAILS_JSON={"cas_number":"97-78-9","citation":"2; 5; 1","dose":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group give...","duration":"6 months","effect":"le Sherman Wistar rats per group were given a single dose (gavage) of 2.5% aqueous Sodium Lauroyl Sarcosine; no deaths occurred in groups given up to 1000 mg/kg, 1 rat each died in the 1200- and 1500- mg/kg groups, 2 died in the 1750 mg/kg group, 4 died after treatment with 2000 mg/kg, 7 died in the 2250 mg/kg group, and all 10 rats died in the group given 2500 g/kg. Weanling rats fed 0.5–2% Sodium Lauroyl Sarcosinate for up to 6 months had no signs of toxicity. During a 2-year feeding study using Wistar rats, the no-observed-effect level of So- dium Lauroyl Sarcosinate was 1000 mg/kg/day. Acute Toxicity Studies Dermal Sodium Myristoyl Sarcosinate. A dose of 2000 mg/kg So- dium Myristoyl Sarcosinate in arachis oil was applied for 24 hours to the backs and flanks of 5 male and 5 female RCC Han:WIST rats using semi-occlusive patches.25 Approxi- mately 10% of the body was covered. Observations were made 0.5, 1, 2, and 4 hours after dosing and then once daily for 14 days. All animals survived until study termination. Very slight erythema, which was observed in 7/10 animals, was fully...","endpoint":"oral toxicity","ingredient":"Fatty Acyl Sarcosines and Sarcosinate Salts","loael_value":"","noael_unit":"mg/kg/day","noael_value":"1000","page":10,"route":"oral","species":"rat","study_id":"PRS719_noael_001"}
openFDA substances 4 endpoints
Source Endpoint Type Value Unit Species Route Duration Study Type Reference
openFDA substances FDA UNII substance identifier LIJ19P3L6F UNII - - - chemical {"approval_status":null,"molecular_formula":"C15H29NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"LIJ19P3L6F"}
openFDA substances FDA UNII substance identifier LIJ19P3L6F UNII - - - chemical {"approval_status":null,"molecular_formula":"C15H29NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"LIJ19P3L6F"}
openFDA substances FDA UNII substance identifier LIJ19P3L6F UNII - - - chemical {"approval_status":null,"molecular_formula":"C15H29NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"LIJ19P3L6F"}
openFDA substances FDA UNII substance identifier LIJ19P3L6F UNII - - - chemical {"approval_status":null,"molecular_formula":"C15H29NO3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"LIJ19P3L6F"}